---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-228902"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-05-18T20:06:05+00:00"
generated_at: "2026-05-18T20:09:41.340643+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum issues $690M zero-coupon convertible notes due 2032; exchanges $237M of 2029 notes

## Summary
- Issued $690M aggregate principal of 0.00% Convertible Senior Notes due 2032, including $90M option exercise.
- Initial conversion price ~$138.94 per share, a 30% premium over $106.88 closing price on pricing date.
- Concurrently exchanged ~$237.2M of existing 4.00% 2029 notes for $475M cash and ~3.22M shares.
- Net proceeds ~$671.6M; remainder for general corporate purposes and potential acquisitions.
- Notes mature June 1, 2032; redeemable after June 6, 2029 under stock price conditions.

## SEC filing metadata
- accession: 0001193125-26-228902
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-05-18T20:06:05+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/d113366d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-228902
- JSON: https://secwatch.observer/filing/0001193125-26-228902.json
- Plain text: https://secwatch.observer/filing/0001193125-26-228902.txt

## Key facts
- Debt Financings
  Mirum Pharmaceuticals, Inc. incurred convertible notes of $690.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.
  - Instrument: convertible notes
  - Principal: $690.0 million aggregate principal amount
  - Counterparty: U.S. Bank Trust Company, National Association
  - Rate: 0.00%
  - Maturity: June 1, 2032
  - Event: incurrence
  source text: On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm
- Material Agreements
  Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $690.0 million (effective 2026-05-15).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association
  - Value: $690.0 million
  - Effective: 2026-05-15
  source text: On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of May 15, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312526228902/0001193125-26-228902-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.